Overcoming cisplatin resistance: Design of novel hydrophobic platinum compounds

Anticancer Research

Volumn 20, Issue 1 A, 2000, Pages 445-449

  Tallen, G ^a   Mock, C ^b   Gangopadhyay, S B ^a   Kangarloo, B ^a   Krebs, B ^b   Wolff, J E A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Brain tumour therapy; Cisplatin DNA binding; Damage recognition; Drug resistance; Proteins

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; PICOLINE DERIVATIVE; PLATINUM DERIVATIVE; PLATINUM METHYLPYRAZINE; PLATINUM METHYLPYRIDINE; PLATINUM PYRIDINE; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TUMOR; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG RESISTANCE; EXCISION REPAIR; FIBROBLAST; HUMAN; HUMAN CELL; HYDROPHOBICITY; LD 50; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BRAIN NEOPLASMS; CHEMISTRY, PHYSICAL; CISPLATIN; CROSS-LINKING REAGENTS; DNA REPAIR; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROBLASTS; GLIOMA; HUMANS; MEDULLOBLASTOMA; MOLECULAR STRUCTURE; ORGANOPLATINUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0034032818     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ferguson PJ: Mechanisms of resistance of human tumors to anticancer drugs of the platinum family. J Otolaryng: 24 (4): 242-252, 1995.
2. Locher PJ, Einhorn LH: Cisplatin. Ann Intern Med 100: 704-713, 1984.
3. Spence AM, Berger MS, Livingston RL, Ali-Osman F, Griffin B: Phase II evaluation of high-dose intravenous cisplatin for treatment of adult recurrent gliomas. J Neurooncol 12: 187-191, 1992.
4. Petsko GA: Heavy metal revival. Nature 377 (19): 580-581, 1995.
5. Takahara PM, Rosenzweig AC, Frederick CAj Lippard SJ: Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377(19): 649-652, 1995.
6. Bewley CA, Gronenhorn AM, Clore GM: Minor groove-binding architectural proteins: Structure, function, and DNA recognition. Ann Rev Biophys Biomol Struct 27: 105-131, 1998.
7. Ohndorf UM, Rould MA, He Q, Pabo CO, Lippard SJ: Basis for recognition of cisplatin-modified DNA by high-mobilitygroup proteins. Nature 399 (17): 708-712, 1999.
8. Zamble DB, Lippard SJ: Cisplatin and DNA repair in cancer chemotherapy. TIBS 20: 435-439, 1995.
9. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T: Cisplatin resistance in human cancers. Pharmacol Ther 52: 385-406, 1991.
10. Eastman A and Schulte N: Enhanced DNA repair as a mechanism of resistance to cis-diamminechloroplatinum (II). Biochemistry 27: 4730-4734, 1988.
11. Dijt FJ, Fichtinger-Schepman AMJ, Berends F, Reedijk J: Formation and repair of cisplatin induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 48: 6058-6062, 1988.
12. Chu G: Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 269 (2): 787-790, 1994.
13. Brown SJ, Kellet PJ, Lippard SJ: 1×1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 261 (5121): 603-605, 1993.
14. Clothia CH: Hydrophobic bonding and accessible surface area in proteins. Nature 248: 338-339, 1974.
15. Edelhoch H and Osborne JC: The thermodynamic basis, of the stability of proteins, nucleic acids and membranes. J Adv Protein Chem 30: 183-250, 1976.
16. Pratt LR and Chandler D: Theory of the hydrophobic effect. J Chem Phys 67: 3683-3704, 1977.
17. Alcalde E, Dinares I, Perez-Garcia L, Roca T: An advatageous synthesis of 2-substituted benzimidazoles using polyphosphoric acid, 2-(pyridyl)-1H-benzimidazoles, 1-alkyl-(1H-benzimidazol-2-yl) pyridinium salts, their homologues and vinylogues. Synthesis 395: 395-398, 1992.
18. Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M: Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacother 16 (1): 16-39, 1996.